HDAC expression and clinical prognosis in human malignancies

This publication has 52 references indexed in Scilit:

• p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape
  The Prostate, 2008
• Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
  British Journal of Cancer, 2008
• Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
  Published by Elsevier ,2008
• Expression of HDAC1 and CBP/p300 in human colorectal carcinomas
  Journal of Clinical Pathology, 2007
• Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
  Nature Biotechnology, 2007
• Anticancer activities of histone deacetylase inhibitors
  Nature Reviews Drug Discovery, 2006
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
  Nature Reviews Cancer, 2006
• Epigenetic therapy of cancer: past, present and future
  Nature Reviews Drug Discovery, 2006
• Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
  Breast Cancer Research and Treatment, 2005
• Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
  The Prostate, 2004